CVS Health Reports Q4 Beat but Maintains Full-Year Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy CVS?
Source: seekingalpha
- Strong Earnings Performance: CVS Health's Q4 2025 revenue grew approximately 8% year-over-year to $105.7 billion, exceeding market expectations by $2.1 billion, although adjusted EPS fell about 8% to $1.09, still beating forecasts by $0.09, indicating robust overall business performance.
- Growth in Health Insurance Segment: Revenue from CVS's Health Care Benefits segment rose about 10% year-over-year to $36.3 billion, with a medical benefit ratio steady at 94.8%, reflecting improvements in government health plans and demonstrating the company's sustained competitiveness in the health insurance market.
- Pharmacy & Consumer Wellness Growth: This segment recorded $37.7 billion in revenue during the period, indicating approximately 12% year-over-year growth, with prescriptions filled increasing by 6.3% on a 30-day equivalent basis, showcasing strong consumer demand that further propelled overall revenue growth.
- Declining Profitability: Despite CVS's diluted EPS rising approximately 77% year-over-year to $2.30, primarily due to a $1.9 billion tax benefit, its gross margin fell by 50 basis points to 5.2%, indicating challenges in cost control, necessitating attention to the recovery of profitability in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 94.180
Low
91.00
Averages
96.71
High
105.00
Current: 94.180
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Surprises with Strong Q1 Revenue and Earnings
- Significant Revenue Growth: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, surpassing analyst expectations of $94.4 billion, with EPS at $2.30, reflecting a 62% increase, indicating a strong rebound in its healthcare and pharmacy segments.
- Upgraded Full-Year Guidance: The company raised its full-year EPS forecast to between $6.24 and $6.44, and operational cash flow expectations increased from $9 billion to at least $9.5 billion, showcasing management's confidence in improving market demand and performance.
- Healthcare Segment Recovery: Revenue from the Aetna health insurance unit rose 3.3% year-over-year to $35.9 billion, with a significant drop in the medical benefit ratio to 84.6%, demonstrating effective cost control and profit enhancement strategies.
- Debt Management Challenges: Despite CVS's long-term debt standing at $86.4 billion, it is gradually reducing total debt by 1.5%, indicating efforts to improve financial health under a capital-intensive acquisition strategy, allowing for future expansion and stock buybacks.
See More
CVS Health Stock Rises 24%: Key Growth Drivers
- Earnings Surprise: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, exceeding analyst expectations of $94.4 billion, with EPS at $2.30, a 62% rise, prompting the company to raise its full-year guidance, now forecasting EPS between $6.24 and $6.44 and operational cash flow of at least $9.5 billion, indicating robust financial health.
- Attractive Dividend Yield: With a current dividend yield of approximately 2.8%, more than double the S&P 500 average, CVS's consistent free cash flow, ranging from $9 billion to $10.5 billion in recent years, supports its dividend payments, enhancing investor confidence.
- Insurance Segment Recovery: CVS's health insurance unit Aetna saw a 3.3% revenue increase to $35.9 billion, with improved margins due to reduced medical utilization costs, as the medical benefit ratio dropped from 87.3% to 84.6%, reflecting strategic adjustments to enhance insurance profitability.
- Debt Concerns Persist: While CVS shows signs of improving profitability, its long-term debt of $86.4 billion remains a drag on performance, with a capital-intensive acquisition strategy leading to significant interest expenses, although total debt has decreased by 1.5% year-over-year to $175 billion, warranting attention on its impact on expansion and stock buybacks.
See More
CVS Health Reaffirms Commitment to Military Families
- Comprehensive Support for Military Families: CVS Health is committed to supporting service members, veterans, and their families through partnerships with nonprofits, providing healthcare access, community solutions, and economic opportunities, ensuring they receive necessary support and resources throughout their service lifecycle.
- Innovative Community Solutions: In North Carolina, CVS Health has launched MFAN's Pantry Restock Program and community support initiatives with Hope For The Warriors, with plans to expand to additional states this year, addressing the real challenges military families face during transitions and enhancing their quality of life.
- Economic Stability and Entrepreneurship Support: In 2025, CVS Health spent $292 million with veteran-owned small businesses, supporting career development and entrepreneurship for veterans and their spouses, helping them gain training and certification within the company's supply chain to promote economic mobility.
- Enhancing Community Connections: CVS Health collaborates with organizations like the Travis Manion Foundation to invest in programs that help veterans and military spouses continue serving their communities, emphasizing the importance of purpose for health and fostering physical wellness and social connections.
See More
ETF Component Trading Dynamics Analysis
- Highest Volume Component: On Tuesday, APA traded over 3.8 million shares, rising about 0.7%, indicating sustained investor interest and possibly reflecting optimistic market expectations for its future performance.
- CVS Health Decline: CVS Health fell approximately 0.9% on Tuesday with over 2.9 million shares traded, suggesting market concerns regarding its recent performance, which may impact its short-term stock price trajectory.
- RES Price Increase: RES was the best-performing component on Tuesday, rising about 1.9%, indicating strong performance in the current market environment and potentially attracting more investor attention.
- COHU Weak Performance: COHU lagged with a decline of about 3.6% on Tuesday, with lower trading volume, reflecting market doubts about its future growth potential, which may lead investors to reassess its investment value.
See More
Misleading Aspects of Stock Valuation
- AbbVie's High Valuation: AbbVie has a P/E ratio exceeding 100, and despite a mere 14% stock price increase over the past year, significantly lagging behind the S&P 500's 24%, this is primarily due to a drastic drop in net income to $188 million from nearly $1.6 billion last year, reflecting the impact of acquisition-related R&D expenses that have raised investor concerns about its high valuation.
- Forward P/E Advantage: Although AbbVie appears overvalued with a high P/E ratio, its forward P/E of 15, which accounts for analyst expectations of future performance, suggests that its actual value may be underestimated, making it an attractive option for long-term investors.
- CVS Health's Earnings Volatility: CVS Health's trailing P/E stands at 42, but the company reported a net loss of nearly $4 billion in Q3 2025, primarily due to a $5.7 billion goodwill impairment, which inflates its P/E ratio; however, its forward P/E drops to just 13, indicating significant investment potential.
- Positive Signal from Decreasing Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, indicating effective cost control, which may lead analysts to upgrade their outlook for the company, further lowering its forward P/E ratio.
See More
AbbVie and CVS Health Stock Analysis Reveals Misleading Valuations
- Misleading Earnings Multiples: AbbVie and CVS Health both exhibit trailing P/E ratios exceeding 40, appearing expensive at first glance; however, non-recurring expenses have distorted their earnings, potentially causing investors to overlook their true value.
- AbbVie's Financial Condition: AbbVie reported net income of $188 million for Q3 2025, a significant drop from nearly $1.6 billion in the prior year, primarily due to a $2.7 billion charge for R&D costs, which inflated its P/E ratio to over 100.
- CVS Health's Losses: CVS Health reported a net loss of nearly $4 billion in Q3 2025, largely due to a $5.7 billion goodwill impairment, resulting in a high trailing P/E of 42, while its forward P/E drops to 13, indicating its actual value may be underestimated.
- Declining Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, suggesting better financial health and potentially attracting more investor interest as the company enhances its bottom line.
See More
CVS Surprises with Strong Q1 Revenue and Earnings
- Significant Revenue Growth: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, surpassing analyst expectations of $94.4 billion, with EPS at $2.30, reflecting a 62% increase, indicating a strong rebound in its healthcare and pharmacy segments.
- Upgraded Full-Year Guidance: The company raised its full-year EPS forecast to between $6.24 and $6.44, and operational cash flow expectations increased from $9 billion to at least $9.5 billion, showcasing management's confidence in improving market demand and performance.
- Healthcare Segment Recovery: Revenue from the Aetna health insurance unit rose 3.3% year-over-year to $35.9 billion, with a significant drop in the medical benefit ratio to 84.6%, demonstrating effective cost control and profit enhancement strategies.
- Debt Management Challenges: Despite CVS's long-term debt standing at $86.4 billion, it is gradually reducing total debt by 1.5%, indicating efforts to improve financial health under a capital-intensive acquisition strategy, allowing for future expansion and stock buybacks.
See More
CVS Health Stock Rises 24%: Key Growth Drivers
- Earnings Surprise: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, exceeding analyst expectations of $94.4 billion, with EPS at $2.30, a 62% rise, prompting the company to raise its full-year guidance, now forecasting EPS between $6.24 and $6.44 and operational cash flow of at least $9.5 billion, indicating robust financial health.
- Attractive Dividend Yield: With a current dividend yield of approximately 2.8%, more than double the S&P 500 average, CVS's consistent free cash flow, ranging from $9 billion to $10.5 billion in recent years, supports its dividend payments, enhancing investor confidence.
- Insurance Segment Recovery: CVS's health insurance unit Aetna saw a 3.3% revenue increase to $35.9 billion, with improved margins due to reduced medical utilization costs, as the medical benefit ratio dropped from 87.3% to 84.6%, reflecting strategic adjustments to enhance insurance profitability.
- Debt Concerns Persist: While CVS shows signs of improving profitability, its long-term debt of $86.4 billion remains a drag on performance, with a capital-intensive acquisition strategy leading to significant interest expenses, although total debt has decreased by 1.5% year-over-year to $175 billion, warranting attention on its impact on expansion and stock buybacks.
See More
CVS Health Reaffirms Commitment to Military Families
- Comprehensive Support for Military Families: CVS Health is committed to supporting service members, veterans, and their families through partnerships with nonprofits, providing healthcare access, community solutions, and economic opportunities, ensuring they receive necessary support and resources throughout their service lifecycle.
- Innovative Community Solutions: In North Carolina, CVS Health has launched MFAN's Pantry Restock Program and community support initiatives with Hope For The Warriors, with plans to expand to additional states this year, addressing the real challenges military families face during transitions and enhancing their quality of life.
- Economic Stability and Entrepreneurship Support: In 2025, CVS Health spent $292 million with veteran-owned small businesses, supporting career development and entrepreneurship for veterans and their spouses, helping them gain training and certification within the company's supply chain to promote economic mobility.
- Enhancing Community Connections: CVS Health collaborates with organizations like the Travis Manion Foundation to invest in programs that help veterans and military spouses continue serving their communities, emphasizing the importance of purpose for health and fostering physical wellness and social connections.
See More
ETF Component Trading Dynamics Analysis
- Highest Volume Component: On Tuesday, APA traded over 3.8 million shares, rising about 0.7%, indicating sustained investor interest and possibly reflecting optimistic market expectations for its future performance.
- CVS Health Decline: CVS Health fell approximately 0.9% on Tuesday with over 2.9 million shares traded, suggesting market concerns regarding its recent performance, which may impact its short-term stock price trajectory.
- RES Price Increase: RES was the best-performing component on Tuesday, rising about 1.9%, indicating strong performance in the current market environment and potentially attracting more investor attention.
- COHU Weak Performance: COHU lagged with a decline of about 3.6% on Tuesday, with lower trading volume, reflecting market doubts about its future growth potential, which may lead investors to reassess its investment value.
See More
Misleading Aspects of Stock Valuation
- AbbVie's High Valuation: AbbVie has a P/E ratio exceeding 100, and despite a mere 14% stock price increase over the past year, significantly lagging behind the S&P 500's 24%, this is primarily due to a drastic drop in net income to $188 million from nearly $1.6 billion last year, reflecting the impact of acquisition-related R&D expenses that have raised investor concerns about its high valuation.
- Forward P/E Advantage: Although AbbVie appears overvalued with a high P/E ratio, its forward P/E of 15, which accounts for analyst expectations of future performance, suggests that its actual value may be underestimated, making it an attractive option for long-term investors.
- CVS Health's Earnings Volatility: CVS Health's trailing P/E stands at 42, but the company reported a net loss of nearly $4 billion in Q3 2025, primarily due to a $5.7 billion goodwill impairment, which inflates its P/E ratio; however, its forward P/E drops to just 13, indicating significant investment potential.
- Positive Signal from Decreasing Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, indicating effective cost control, which may lead analysts to upgrade their outlook for the company, further lowering its forward P/E ratio.
See More
AbbVie and CVS Health Stock Analysis Reveals Misleading Valuations
- Misleading Earnings Multiples: AbbVie and CVS Health both exhibit trailing P/E ratios exceeding 40, appearing expensive at first glance; however, non-recurring expenses have distorted their earnings, potentially causing investors to overlook their true value.
- AbbVie's Financial Condition: AbbVie reported net income of $188 million for Q3 2025, a significant drop from nearly $1.6 billion in the prior year, primarily due to a $2.7 billion charge for R&D costs, which inflated its P/E ratio to over 100.
- CVS Health's Losses: CVS Health reported a net loss of nearly $4 billion in Q3 2025, largely due to a $5.7 billion goodwill impairment, resulting in a high trailing P/E of 42, while its forward P/E drops to 13, indicating its actual value may be underestimated.
- Declining Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, suggesting better financial health and potentially attracting more investor interest as the company enhances its bottom line.
See More
